Read by QxMD icon Read

Idiopathic urticaria

(no author information available yet)
BACKGROUND: Chronic idiopathic urticaria (CIU)/spontaneous urticaria (CSU) is defined by the presence of wheals,angioedema, or both for 6 weeks, with or without an identifiable trigger. Real-world health care data among children withCIU/CSU remain scarce. OBJECTIVES: To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (12 years old) and to compare these with pediatric patients without CIU/CSU. METHODS: A commercial administrative claims data base (September 2013 to June 2016) was used...
March 7, 2018: Allergy and Asthma Proceedings:
(no author information available yet)
BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients withCIU/CSU. METHODS: Patients with CIU/CSU (ages greater than or equal to 12 years) initiated on omalizumab (index date) with greater than or equal to 12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016)...
February 19, 2018: Allergy and Asthma Proceedings:
James J Crawford, Adam R Johnson, Dinah L Misner, Lisa D Belmont, Georgette M Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W Lubach, Brent S McKenzie, Daniel Fred Ortwine, Leah Schutt, Suzanne Tay, Binqing Wei, Karin Reif, Lichuan Liu, Harvey Wong, Wendy B Young
Btk is a non-receptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Pre-clinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and pre-clinical characterization of a potent, selective, and non-covalent Btk inhibitor currently in clinical development. GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease, and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis...
February 19, 2018: Journal of Medicinal Chemistry
Zhe Hou, Brian R Hinds, Philip R Cohen
Neutrophilic urticarial dermatosis (NUD) is a useful diagnostic term for urticarial lesions that are less pruritic and more painful than conventional urticaria. The histopathologic features include neutrophilic infiltrates in the interstitial dermis with a higher density than idiopathic urticaria. NUD has been associated with several systemic conditions, which are predominantly autoimmune and autoinflammatory in nature. A woman with Crohn disease who developed NUD is described. Literature reports of other conditions in which neutrophilic urticarial dermatosis have been observed are also reviewed and summarized...
November 15, 2017: Dermatology Online Journal
Man Cheung Chung, Christine Symons, Jane Gilliam, Edward R Kaminski
BACKGROUND: There is evidence suggesting that posttraumatic stress disorder (PTSD) symptom severity and CIU severity are linked and partially mediated by the high-anxious defense mechanism. What is unclear is whether emotional suppression, as a defense serving the opposite purpose for high-anxious defense, can also act as a mediator and whether this mediational effect is partly influenced by time since trauma and trauma type. AIMS: To investigate whether emotional suppression mediated the links between PTSD and CIU symptom severities, and PTSD and psychiatric co-morbid symptom severities...
February 12, 2018: Journal of Mental Health
Jonathan A Bernstein, Abhishek Kavati, Michael D Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham
Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice...
February 12, 2018: Expert Opinion on Biological Therapy
Paul V Williams, Abhishek Kavati, Dominic Pilon, Yongling Xiao, Maryia Zhdanava, Maria-Magdalena Balp, Patrick Lefebvre, Benjamin Ortiz, Vivian Hernandez-Trujillo
INTRODUCTION: Few studies have described chronic idiopathic/spontaneous urticaria (CIU/CSU) healthcare burden in adults, while this information remains largely unknown in children. We aimed to describe treatment patterns, healthcare resource utilization (HRU), and costs in CIU/CSU pediatric patients, as well as to compare HRU and costs in CIU/CSU and CIU/CSU-free pediatric patients. METHODS: Medicaid claims from four states (09/01/2013-03/31/2016) were used to identify patients less than 12 years old...
February 10, 2018: Dermatology and Therapy
Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Liya Wang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized. OBJECTIVE: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world...
December 19, 2017: Journal of Managed Care & Specialty Pharmacy
M Sánchez-Borges, A Capriles-Hulett, F Caballero-Fonseca, L González-Aveledo
Background. Currently there are no biomarkers useful to predict the future evolution and the therapeutic response in patients with chronic spontaneous urticaria (CSU). Objective. To review the available information on biomarkers that might be applied for the follow up of the response to guideline recommended therapies for CSU. Methods. A review of the medical literature on CSU potential clinical and laboratory biomarkers in PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, chronic spontaneous urticaria, antihistamines (AHs), omalizumab (OMA), cyclosporine (CyA), and treatment...
January 2018: European Annals of Allergy and Clinical Immunology
Jennifer A Dantzer, Robert A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity, and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
January 5, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
Si Hui Goh, Jian Yi Soh, Wenyin Loh, Khai Pin Lee, Sze Chin Tan, Wei Jian Kenneth Heng, Irwani Ibrahim, Bee Wah Lee, Wen Chin Chiang
BACKGROUND: The study objective was to compare age-related differences in the cause and clinical presentation of anaphylaxis. METHODS: We conducted a prospective study of patients visiting the emergency department for anaphylaxis. Data were collected from 3 emergency departments from 1 April 2014 to 31 December 2015. Patient electronic records with the diagnoses of allergy, angioedema, urticaria, and anaphylaxis (ICD-9 codes 9953, 9951, 7080, 9950, 7089) were screened and cases fulfilling World Allergy Organisation criteria for anaphylaxis were included...
January 5, 2018: International Archives of Allergy and Immunology
Oliver Schmetzer, Elisa Lakin, Fatih A Topal, Patricia Preusse, Denise Freier, Martin K Church, Marcus Maurer
BACKGROUND: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. OBJECTIVE: We sought to identify autoallergic targets of IgE in patients with CSU. METHODS: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins...
December 5, 2017: Journal of Allergy and Clinical Immunology
Marcus Maurer, Allen Kaplan, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Thomas B Casale
No abstract text is available yet for this article.
November 10, 2017: Journal of Allergy and Clinical Immunology
Liya Wang, Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
OBJECTIVE: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US. METHODS: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD®) augmented with medical record data to identify CIU patients newly-treated with omalizumab (≥4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with ≥6 months pre- and ≥12 months post-index health plan eligibility...
January 2018: Current Medical Research and Opinion
Thomas B Casale, Patrick H Win, Jonathan A Bernstein, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Evgeniya N Antonova, Thomas Murphy, Mark D Scarupa, Howard Sofen, Allen Kaplan
No abstract text is available yet for this article.
October 13, 2017: Journal of the American Academy of Dermatology
M Theiler, A Schwieger-Briel, L Weibel
BACKGROUND: Skin infections account for 40% of emergency visits in pediatric dermatology. It is important to promptly recognize skin infections with potential complications and initiate treatment. However some characteristic skin findings may imitate skin infections and are often misdiagnosed. OBJECTIVES: To illustrate frequent pediatric skin infections and pitfalls in view of imitators and differential diagnoses. MATERIALS AND METHODS: A photo quiz is presented with the discussion of a selection of acute pediatric skin infections in comparison to their infectious or noninfectious differential diagnoses...
October 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
Julie K Kim, Daniel Har, L Steven Brown, David A Khan
BACKGROUND: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). OBJECTIVES: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. METHODS: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed...
September 6, 2017: Journal of Allergy and Clinical Immunology in Practice
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging...
2017: Allergy, Asthma, and Clinical Immunology
Hiroyuki Murota, Hiroaki Azukizawa, Ichiro Katayama
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association...
August 17, 2017: Chinese Journal of Integrative Medicine
Mariana Castells
Anaphylaxis is the most severe and frightening of the allergic reactions, placing patients at high risk and demanding prompt recognition and immediate management by health care providers. Yet because its symptoms imitate those of other diseases, such as asthma and urticaria, current data suggest that its diagnosis is often missed, with underuse of tryptase measurement; its treatment is delayed, with little use of epinephrine; and its underlying cause or causes are poorly investigated. Deaths from anaphylaxis are difficult to investigate because of miscoding...
August 2017: Journal of Allergy and Clinical Immunology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"